Milestone Pharmaceuticals in the spotlight (part IV)

Phase 3 results and stock momentum heading into 2023

This morning Milestone Pharmaceuticals (MIST) announced that its Phase 3 trial met the primary endpoint, with 64.3% of patients self-administering etripamil seeing their heart rate convert to normal within 30 minutes compared to 31.2% on placebo (HR = 2.62, p<0.001). The stock went down significantly throughout the day, since there are no near-term cata…